JPMorgan initiated coverage of Upstream Bio (UPB) with an Overweight rating and $38 price target Upsteam’s lead asset is verekitug, a recombinant human IgG1 monoclonal antibody that binds the thymic ...
Fintel reports that on February 24, 2025, JP Morgan upgraded their outlook for bluebird bio (LSE:0HOH) from Underweight to Neutral. As of January 28, 2025, the average one-year price target for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results